Home › Funds › W.G. Shaheen & Associates DBA Whitney & Co › VRTX

W.G. Shaheen & Associates DBA Whitney & Co position in VRTX

VERTEX PHARMACEUTICALS INC · Health Care

W.G. Shaheen & Associates DBA Whitney & Co reported holding 44,065 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$23.0M, representing 1.64% of its reported portfolio and ranking #18 among its reported holdings. W.G. Shaheen & Associates DBA Whitney & Co has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)44.06K sh
Reported value held$23.04M
Portfolio Weight1.64%
First reportedQ3 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How W.G. Shaheen & Associates DBA Whitney & Co's VRTX position evolved

W.G. Shaheen & Associates DBA Whitney & Co first disclosed a stake in VRTX in Q3 2023 at 49,935 shares (US$17.4M). The position peaked in Q2 2024 at 51,154 shares, worth US$24.0M. Across 13 filings, W.G. Shaheen & Associates DBA Whitney & Co increased the stake 5 time(s), trimmed it 3 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 44,065 shares valued at US$23.0M — a reduction of -649 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 49.94K $17.36M New
Q4 2023 50.03K $20.36M Hold
Q1 2024 50.56K $21.13M Add
Q2 2024 51.15K $23.98M Add
Q3 2024 43.41K $20.19M Reduce
Q4 2024 43.25K $17.42M Hold
Q1 2025 43.80K $21.23M Add
Q2 2025 43.81K $19.50M Hold
Q3 2025 43.56K $17.06M Reduce
Q4 2025 44.16K $20.02M Add
Q1 2026 44.12K $19.70M Hold
Q2 2026 44.71K $22.21M Add
Q3 2026 44.06K $23.04M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRTX and 13F data

VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 32 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$13.58B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRTX

All VRTX fund holders →

FAQ

How long has W.G. Shaheen & Associates DBA Whitney & Co held VRTX?

W.G. Shaheen & Associates DBA Whitney & Co has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is W.G. Shaheen & Associates DBA Whitney & Co's current position in VRTX?

As of Q3 2026, W.G. Shaheen & Associates DBA Whitney & Co holds 44.06K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $23.04M, representing 1.64% of its reported portfolio and ranking #18.

Has W.G. Shaheen & Associates DBA Whitney & Co been buying or selling VRTX?

In the latest 13F filing (Q3 2026), W.G. Shaheen & Associates DBA Whitney & Co reduced its position in VRTX. The position peaked in Q2 2024 at 51.15K shares.

Which other funds hold VRTX?

Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 32 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.